US 7,510,728 B2
	Solid preparations
Masahiko Koike, Toyonaka (Japan)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (Japan)
Appl. No. 10/398,434 PCT Filed Oct. 05, 2001, PCT No. PCT/JP01/08785 § 371(c)(1), (2), (4) Date Apr. 02, 2003, PCT Pub. No. WO02/30400, PCT Pub. Date Apr. 18, 2002.
Claims priority of application No. 2000-313105 (JP), filed on Oct. 06, 2000; and application No. 2000-313106 (JP), filed on Oct. 06, 2000.
Prior Publication US 2004/0033258 A1, Feb. 19, 2004
Int. Cl. A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 9/30 (2006.01); A61K 9/32 (2006.01); A61K 9/36 (2006.01)

U.S. Cl. 424—464  [424/465; 424/474; 424/475; 424/479; 424/480; 424/482]

4 Claims

1. A solid pharmaceutical preparation in the form of a tablet comprising 1) pioglitazone hydrochloride, 2) 5 to 97 parts by weight of D-mannitol, 3) 1 to 50 parts by weight of sodium carboxymethylcellulose, 4) 0.1 to 15 parts by weight of sodium glutamate, and 5) carboxymethylcellulose, all parts by weight being based on 100 parts by weight of the solid pharmaceutical preparation, wherein the time for complete disintegration of the solid pharmaceutical preparation by human saliva in the oral cavity of a healthy adult ranges from 5 to 90 seconds.